SERB_Pharmaceuticals acquires Idefirix rights
Analysis based on 7 articles · First reported May 19, 2026 · Last updated May 19, 2026
The acquisition of Imlifidase rights by SERB Pharmaceuticals>>> from GT Biopharma>>> is expected to positively impact both companies. GT Biopharma>>> will receive a significant cash injection, potentially boosting its stock price, while SERB Pharmaceuticals>>> expands its portfolio in a specialized market, which could lead to increased revenue and market share.
SERB Pharmaceuticals>>> has entered into an agreement to acquire the exclusive development and commercialization rights to Imlifidase (imlifidase) in the European Union>>>, United Kingdom>>>, Switzerland>>>, Norway>>>, Liechtenstein>>>, Iceland>>>, and the Europe, the Middle East and Africa>>> region from GT Biopharma>>> for 115 million euros. Imlifidase is a treatment for highly sensitized adult patients awaiting kidney transplants from deceased donors, addressing a significant unmet medical need. Under the terms, GT Biopharma>>> will receive an upfront payment of 110 million euros and an additional 5 million euros upon acceptance of the filing for full approval of Imlifidase by the European Union — European Medicines Agency>>>. GT Biopharma>>> will support SERB Pharmaceuticals>>> in the EMA filing and review process, while SERB Pharmaceuticals>>> will take over responsibility for post-authorization studies. The transaction is subject to regulatory approval and is expected to close within 60 days. This deal allows SERB Pharmaceuticals>>> to expand its presence in rare and urgent conditions and provides GT Biopharma>>> with substantial capital.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard